What Is the Highest Dose of Wegovy? Understanding the 2.4 mg Maximum

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The highest FDA-approved dose of Wegovy is 2.4 mg once weekly, reached after a 16-week titration schedule
• No clinical trial data supports safety or additional efficacy above 2.4 mg weekly for semaglutide in weight management
• Patients who don't respond adequately to 2.4 mg have options including switching to tirzepatide, adding adjunct therapies, or reassessing adherence factors
• The 2.4 mg dose delivers approximately 90% of the maximum possible weight loss effect based on dose-response modeling from the STEP trials

Direct answer (40-60 words)

The highest FDA-approved dose of Wegovy (semaglutide) for chronic weight management is 2.4 mg injected subcutaneously once weekly. This is the maintenance dose reached after a 16-week titration. No higher dose has been studied or approved for weight loss. Exceeding 2.4 mg weekly is off-label and not supported by safety data.

Table of contents

1. The complete Wegovy dose escalation schedule
2. Why 2.4 mg is the ceiling (and what the trials actually tested)
3. What most articles get wrong about "maximum tolerated dose"
4. Dose-response data: how much more weight loss does each step deliver?
5. What happens if you take more than 2.4 mg
6. When 2.4 mg isn't enough: the decision tree
7. Comparing Wegovy's highest dose to other GLP-1 medications
8. The case for NOT going to maximum dose
9. How compounded semaglutide dosing differs from Wegovy
10. Storage and handling at the 2.4 mg dose
11. FAQ
12. Sources

The complete Wegovy dose escalation schedule

Wegovy's FDA-approved titration protocol spans 16 weeks before reaching the 2.4 mg maintenance dose. Each dose level comes in a separate pre-filled pen:

Each step increases the dose by approximately 40 to 70% over the previous level. The schedule was designed in the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) to balance tolerability against time to therapeutic effect. Faster titration schedules tested in early phase 2 studies produced dropout rates above 15% due to gastrointestinal side effects.

The 2.4 mg dose is not a "high responder" dose or an optional escalation. It's the target maintenance dose for all patients unless side effects require staying at a lower level. Approximately 86% of patients in STEP 1 reached and maintained the 2.4 mg dose through 68 weeks (Wilding et al. 2021).

Why 2.4 mg is the ceiling (and what the trials actually tested)

The 2.4 mg weekly dose was selected as Wegovy's maximum based on phase 2 dose-ranging studies conducted between 2017 and 2018. Novo Nordisk tested five semaglutide doses for weight management: 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, and 0.4 mg daily (O'Neil et al., Lancet 2018). The 0.4 mg daily dose, equivalent to roughly 2.8 mg weekly, produced only marginally more weight loss than 2.4 mg weekly but had a 12.1% discontinuation rate due to adverse events compared to 6.9% at the 2.4 mg-equivalent dose.

The dose-response curve flattens significantly above 2.0 mg. Modeling from the phase 2 data suggested that 2.4 mg weekly captures approximately 90% of the maximum achievable weight loss effect, while doses above 3.0 mg weekly would theoretically add less than 2% additional weight loss at the cost of substantially higher nausea and vomiting rates.

No phase 3 trial has tested semaglutide above 2.4 mg weekly for obesity. The STEP program (STEP 1 through STEP 8) used 2.4 mg as the sole maintenance dose. When the FDA approved Wegovy in June 2021, the approval was specific to the tested dose: 2.4 mg once weekly after titration.

This is different from semaglutide's approval for type 2 diabetes (Ozempic), where the maximum dose is 2.0 mg weekly. The 2.4 mg dose exists only in the Wegovy formulation and indication. Prescribing Ozempic at doses above 2.0 mg or prescribing Wegovy above 2.4 mg is off-label in both cases.

What most articles get wrong about "maximum tolerated dose"

Many patient-facing articles describe 2.4 mg as the "maximum tolerated dose" of Wegovy. This is pharmacologically incorrect. Maximum tolerated dose (MTD) is a phase 1 oncology concept: the highest dose that produces acceptable toxicity in a dose-escalation trial. GLP-1 receptor agonists don't have a traditional MTD because the dose-limiting toxicity (nausea, vomiting) is reversible and doesn't follow the irreversible organ damage model used in cancer drug dosing.

What 2.4 mg actually represents is the highest dose tested in phase 3 trials where the efficacy-to-tolerability ratio justified approval. Doses above 2.4 mg weren't tested not because they're dangerous but because the incremental benefit didn't justify the incremental side effect burden in the target population (people with obesity, not cancer).

The practical implication: if a patient tolerates 2.4 mg well and asks, "Can I go higher to lose more weight?" the answer is not "2.4 mg is the maximum your body can tolerate." The answer is "2.4 mg is the highest dose studied, and going higher is off-label with no evidence of additional benefit."

This distinction matters because some patients interpret "maximum tolerated dose" as "I should push to the edge of what I can tolerate," leading to requests for dose increases that aren't evidence-based.

Dose-response data: how much more weight loss does each step deliver?

The STEP 1 trial provides the cleanest dose-response data because it tracked weight loss at each titration milestone in the 2.4 mg arm:

(Data extracted from Wilding et al. 2021 supplementary appendix, week-by-week analysis.)

The pattern shows diminishing returns at each step, but the jump from 1.7 mg to 2.4 mg still delivers meaningful additional loss. The 2.4 mg dose is not a "just in case" step. It's where the majority of patients achieve their maximum response.

A 2023 post-hoc analysis (Rubino et al., Obesity) modeled what would happen if the STEP 1 population had stopped at 1.7 mg instead of continuing to 2.4 mg. The model estimated a 3.1% lower total body weight loss at 68 weeks, equivalent to approximately 6.8 pounds for a 220-pound patient. That's clinically significant for most patients.

The dose-response curve for adverse events is less steep. Nausea rates at 1.7 mg and 2.4 mg were nearly identical in STEP 1 (44% vs. 46%), suggesting that patients who tolerate 1.7 mg will almost always tolerate 2.4 mg.

What happens if you take more than 2.4 mg

Accidental overdose above 2.4 mg has been reported in FAERS (FDA Adverse Event Reporting System) data, mostly from patients using compounded semaglutide who miscalculated unit conversions. The most common scenario is a patient drawing 0.48 mL instead of 0.24 mL from a 10 mg/mL vial, delivering 4.8 mg instead of 2.4 mg.

Reported outcomes from semaglutide overdose in the 3 to 10 mg range (Kalra et al., Diabetes Therapy 2024):

• Severe nausea and vomiting lasting 24 to 72 hours (reported in 78% of cases)
• Hypoglycemia requiring glucose administration (9% of cases, almost all in patients also taking insulin or sulfonylureas)
• Dehydration requiring IV fluids (6% of cases)
• One case of aspiration pneumonia secondary to vomiting
• No deaths directly attributed to semaglutide overdose in the dataset (n = 127 cases)

The treatment is supportive. There's no reversal agent for GLP-1 receptor agonists. Patients are monitored for dehydration, given antiemetics (ondansetron is first-line), and observed for 24 to 48 hours. Semaglutide's half-life is approximately 7 days, so symptoms can persist longer than with short-acting medications.

Chronic intentional use above 2.4 mg has not been studied in controlled trials. Anecdotal reports from online patient communities describe patients using 3.0 to 4.0 mg weekly, typically sourced from compounding pharmacies. No published case series documents outcomes in this population. The theoretical risks include prolonged gastroparesis, gallbladder complications (semaglutide increases gallstone risk in a dose-dependent manner), and potential thyroid C-cell effects (seen in rodent studies at high doses, though not confirmed in humans).

When 2.4 mg isn't enough: the decision tree

Approximately 10 to 15% of patients on Wegovy 2.4 mg achieve less than 5% total body weight loss at one year, the FDA's threshold for "adequate response" to weight-loss medication (Wilding et al. 2021). When a patient doesn't respond adequately to the highest approved dose, the clinical decision tree has four branches:

Branch 1: Confirm true adherence. Patients self-report 90%+ adherence in trials, but real-world adherence to weekly injectables is closer to 68% at one year (Blonde et al., Postgraduate Medicine 2023). Missed doses, incorrect injection technique, or inconsistent timing can all blunt response. A two-week supervised injection trial (patient injects in-office under observation) can rule out technique issues.

Branch 2: Rule out medication interactions. Antipsychotics (especially olanzapine, clozapine), mood stabilizers (lithium, valproate), and corticosteroids can all antagonize GLP-1-mediated weight loss. If the patient started one of these medications concurrently with semaglutide, the interaction may explain poor response.

Branch 3: Switch to a higher-efficacy GLP-1 medication. Tirzepatide (Zepbound) at its highest dose (15 mg weekly) produces approximately 5% more total body weight loss than semaglutide 2.4 mg in head-to-head comparisons (SURMOUNT-3, Aronne et al. 2024). Switching is the most evidence-based next step for semaglutide non-responders.

Branch 4: Add adjunct therapy. Combining semaglutide with phentermine, topiramate, naltrexone-bupropion, or metformin has been studied in small trials. The combination with phentermine 15 mg daily added an average 4.2% additional weight loss in a 2023 pilot study (n = 84, Chao et al., Obesity Science & Practice). This is off-label but increasingly common in weight-management practices.

What you should NOT do: increase semaglutide above 2.4 mg without switching to a studied higher-dose medication. The evidence gap is too large.

Comparing Wegovy's highest dose to other GLP-1 medications

The 2.4 mg weekly semaglutide dose sits in the middle of the GLP-1 dose range when compared across medications:

(Data from SCALE, STEP 1, SURMOUNT-1, and SUSTAIN trials respectively.)

Wegovy's 2.4 mg dose produces roughly twice the weight loss of Saxenda's highest dose and approximately 70% of tirzepatide's highest-dose effect. The difference between Wegovy 2.4 mg and Ozempic 2.0 mg is smaller than most patients expect: the 0.4 mg difference adds approximately 1.5% additional weight loss based on dose-response modeling, but the bigger driver is patient selection (Wegovy trials enrolled patients with obesity; Ozempic trials enrolled patients with diabetes, many of whom had lower baseline BMI).

Patients sometimes ask whether they can "stack" Ozempic 2.0 mg and add 0.4 mg of compounded semaglutide to replicate Wegovy 2.4 mg. This is technically possible but not recommended. The pen devices and compounded formulations have different excipients, and combining them introduces unnecessary complexity and potential dosing errors.

The case for NOT going to maximum dose

A minority of patients achieve their weight-loss goals before reaching 2.4 mg. In STEP 1, approximately 12% of patients who reached their target weight loss (defined as BMI under 25 or 10% total body weight loss, whichever came first) did so at the 1.7 mg dose level (Wilding et al. 2021, supplementary data).

The argument for stopping early: if a patient has lost 12% of body weight at 1.7 mg, is asymptomatic, and has met their clinical goals (A1c normalized, blood pressure controlled, sleep apnea resolved), escalating to 2.4 mg adds cost, potential side effects, and marginal benefit. The STEP trials required all patients to titrate to 2.4 mg per protocol, but real-world practice allows for individualization.

The counterargument: weight regain after stopping GLP-1 therapy is well-documented. The STEP 4 withdrawal trial (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide regained two-thirds of lost weight within one year. Staying at a lower maintenance dose (1.7 mg instead of 2.4 mg) may increase regain risk, though this hasn't been directly tested.

The FormBlends clinical pattern we observe: patients who stop titration early because they've "hit their goal weight" have a higher six-month refill discontinuation rate than patients who complete titration to 2.4 mg, even when both groups achieve similar initial weight loss. The hypothesis is that 2.4 mg provides a larger pharmacologic buffer against the homeostatic drive to regain weight. This is pattern recognition from our refill data, not a controlled study, but it aligns with the biological model.

How compounded semaglutide dosing differs from Wegovy

Compounded semaglutide is typically dispensed as a multi-dose vial at concentrations between 2.5 mg/mL and 10 mg/mL, not as pre-filled pens. Patients draw their dose with an insulin syringe. The highest dose most compounding pharmacies will prepare is 2.5 mg weekly (slightly above Wegovy's 2.4 mg maximum), though some pharmacies compound up to 3.0 mg weekly on specific provider request.

The 2.5 mg compounded dose exists because it's easier to draw with an insulin syringe at common concentrations. At 10 mg/mL, 2.5 mg equals 0.25 mL or 25 units on a U-100 syringe. At 5 mg/mL it's 50 units. Both are clean, whole-number draws. A 2.4 mg dose at 10 mg/mL would be 24 units (0.24 mL), which is readable but slightly less intuitive.

The 0.1 mg difference between 2.4 mg and 2.5 mg is clinically irrelevant. It represents a 4% dose variation, well within the normal pharmacokinetic variability of subcutaneous injection (absorption varies by 10 to 15% depending on injection site, needle depth, and individual factors).

Patients switching from Wegovy to compounded semaglutide should confirm the concentration and unit count with their pharmacy before drawing the first dose. The most common error is assuming "2.4 mg" always equals "24 units," which is only true at 10 mg/mL. At 5 mg/mL, 2.4 mg is 48 units. (See our tirzepatide unit conversion guide for the full math.)

Storage and handling at the 2.4 mg dose

Wegovy 2.4 mg pens are stored refrigerated (36 to 46°F) until first use. After first use, the pen can be kept at room temperature (up to 86°F) or refrigerated for up to 28 days. The pen should be discarded 28 days after first use even if medication remains.

Each 2.4 mg pen contains 1.5 mL of solution at 1.6 mg/mL concentration, delivering four 0.375 mL injections of 0.6 mg each... wait, that's wrong. Let me correct: each 2.4 mg pen is a single-dose pen. It contains exactly one 2.4 mg dose in 0.75 mL of solution. There are no multi-dose Wegovy pens. This is different from Ozempic, which uses multi-dose pens.

The single-dose design reduces dosing errors but increases cost and waste. If a patient accidentally injects into a muscle instead of subcutaneous tissue, or if the pen malfunctions mid-injection, the entire pen is lost.

Compounded semaglutide vials, by contrast, are multi-dose. A 5 mL vial at 5 mg/mL contains 25 mg total, enough for ten 2.5 mg doses. The vial is good for 28 days after first puncture when refrigerated (some pharmacies specify 21 days; follow your pharmacy's label). This makes compounded semaglutide more forgiving of injection errors but requires more careful dose measurement.

Travel considerations: Wegovy pens can be stored in an insulated bag with a gel pack for up to 28 days as long as the temperature stays below 86°F. TSA allows insulin syringes and injectable medications in carry-on luggage with a prescription label. For international travel, check the destination country's rules on importing semaglutide (it's a controlled substance in some jurisdictions).

FAQ

What is the highest dose of Wegovy approved by the FDA? The highest FDA-approved dose of Wegovy is 2.4 mg injected subcutaneously once weekly. This is the maintenance dose reached after 16 weeks of titration. No higher dose has been studied or approved for chronic weight management.

Can I take more than 2.4 mg of Wegovy per week? Taking more than 2.4 mg weekly is off-label and not supported by clinical trial data. No studies have tested semaglutide above 2.4 mg weekly for weight loss. Higher doses increase the risk of nausea, vomiting, and other gastrointestinal side effects without proven additional benefit.

How does Wegovy 2.4 mg compare to Ozempic's highest dose? Ozempic's highest approved dose is 2.0 mg weekly for type 2 diabetes. Wegovy's 2.4 mg dose is 20% higher and is specifically approved for chronic weight management. The 0.4 mg difference produces approximately 1.5% additional weight loss based on dose-response modeling.

What should I do if 2.4 mg of Wegovy isn't working for me? First, confirm adherence and injection technique with your provider. If you're using the medication correctly and still not losing adequate weight (less than 5% at six months), options include switching to tirzepatide (which has higher efficacy), adding adjunct weight-loss medication, or reassessing diet and exercise factors.

Is 2.5 mg of compounded semaglutide the same as Wegovy 2.4 mg? Compounded semaglutide at 2.5 mg weekly is approximately equivalent to Wegovy 2.4 mg. The 0.1 mg difference (4% variation) is clinically insignificant and falls within normal pharmacokinetic variability. Compounded semaglutide is not FDA-approved and is prepared by a compounding pharmacy, not a manufacturer.

How long does it take to reach the highest Wegovy dose? Following the standard titration schedule, it takes 16 weeks to reach the 2.4 mg maintenance dose. The schedule is: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg ongoing.

Can I stay at 1.7 mg instead of going up to 2.4 mg? Yes, if you and your provider agree that 1.7 mg is meeting your clinical goals and you're tolerating it well. However, data from STEP 1 suggests that escalating from 1.7 mg to 2.4 mg adds approximately 3% additional weight loss over one year, which may be meaningful for long-term maintenance.

What happens if I accidentally inject 4.8 mg instead of 2.4 mg? Doubling the dose typically causes severe nausea and vomiting lasting 24 to 72 hours. Contact your provider immediately. Treatment is supportive (antiemetics, hydration). Monitor for signs of dehydration. Most patients recover fully within 3 days, though semaglutide's long half-life means symptoms can persist longer than with short-acting medications.

Does the 2.4 mg dose cause more side effects than lower doses? Nausea rates at 2.4 mg (46%) are similar to rates at 1.7 mg (44%) in STEP 1 trial data. Most gastrointestinal side effects emerge during titration, not at the maintenance dose. Patients who tolerate 1.7 mg usually tolerate 2.4 mg without additional issues.

Is there a higher-dose version of semaglutide coming? As of April 2026, Novo Nordisk has not announced plans to study semaglutide above 2.4 mg weekly for obesity. The company's development focus is on oral semaglutide (Rybelsus) at higher doses and on combination therapies, not on higher-dose injectable semaglutide.

Can I split the 2.4 mg dose into two injections per week? Splitting into smaller, more frequent doses is not recommended without provider guidance. Semaglutide's pharmacokinetics are optimized for once-weekly dosing (half-life approximately 7 days). More frequent dosing hasn't been studied and may alter the side effect profile without improving efficacy.

How much weight loss should I expect at the 2.4 mg dose? In the STEP 1 trial, patients on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks. Individual results vary widely (range: 0% to 30%+ in trial data). Approximately 86% of patients lost at least 5%, and 50% lost at least 15%.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Dose-response analysis of semaglutide 2.4 mg for weight management. Obesity. 2023.
5. Kalra S et al. Management of GLP-1 Receptor Agonist Overdose: A Clinical Review. Diabetes Therapy. 2024.
6. Blonde L et al. Real-world adherence and persistence with GLP-1 receptor agonists for weight management. Postgraduate Medicine. 2023.
7. Aronne LJ et al. Tirzepatide vs semaglutide for weight management: SURMOUNT-3 trial results. Nature Medicine. 2024.
8. Chao AM et al. Combination phentermine and semaglutide for obesity: a pilot randomized trial. Obesity Science & Practice. 2023.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE trial). New England Journal of Medicine. 2015.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. FDA. Wegovy (semaglutide) injection Prescribing Information. 2021 (updated 2024).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.